Fig. 7

The macrophage-related gene signature was predictive of drug sensitivity/resistance to the targeted therapy. a, b Patients who received targeted therapy in the independent validation set were predicted to be drug-sensitive or drug-resistant based on the risk score calculated from the macrophage-related gene signature using optimal cutoff values according to the 3-year survival (a) or 5-year survival (b) outcomes after the molecularly targeted therapy. K–M survival curves of the patients predicted to be sensitive (blue) and resistant (red) were plotted, and the statistical significance was assessed using the log-rank test. All p values were less than 0.0001. c, d Accuracy of the macrophage-related gene signature for predicting drug sensitivity to the targeted therapy in glioma patients in comparison with other signatures. Signature 1: macrophage-related gene signature. Signature 2: EGFR gene signature. Signature 3: Cheng et al. signature. Signature 4: IGF1/IGF1R-mediated pathways signature. The prediction accuracies of these signatures evaluated by the 3-year survival (c) or 5-year survival (d) outcomes were assessed by the AUCs of the ROC curves based on the validation set. AUC values of each signature were shown, and p values were computed to assess the statistical significance of superior predictive power of the signature 1 against the other two signatures